Wall Street brokerages expect LeMaitre Vascular Inc (NASDAQ:LMAT) to post $0.19 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for LeMaitre Vascular’s earnings. LeMaitre Vascular also posted earnings per share of $0.19 in the same quarter last year. The company is scheduled to announce its next earnings results on Wednesday, April 24th.
On average, analysts expect that LeMaitre Vascular will report full-year earnings of $0.84 per share for the current financial year, with EPS estimates ranging from $0.82 to $0.85. For the next fiscal year, analysts anticipate that the company will post earnings of $0.94 per share, with EPS estimates ranging from $0.90 to $1.00. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, February 19th. The medical instruments supplier reported $0.24 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.24. The company had revenue of $28.39 million for the quarter, compared to analyst estimates of $26.06 million. LeMaitre Vascular had a return on equity of 17.71% and a net margin of 21.73%.
Shares of NASDAQ LMAT traded down $0.26 during mid-day trading on Friday, reaching $29.82. 74,000 shares of the company’s stock were exchanged, compared to its average volume of 155,952. The firm has a market cap of $581.00 million, a P/E ratio of 27.73, a P/E/G ratio of 2.94 and a beta of 1.05. LeMaitre Vascular has a twelve month low of $21.79 and a twelve month high of $41.28.
In related news, insider Trent G. Kamke sold 16,604 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, February 22nd. The stock was sold at an average price of $29.63, for a total value of $491,976.52. Following the sale, the insider now owns 19,857 shares of the company’s stock, valued at approximately $588,362.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.30% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of LMAT. BlackRock Inc. boosted its stake in LeMaitre Vascular by 4.9% in the 3rd quarter. BlackRock Inc. now owns 2,545,148 shares of the medical instruments supplier’s stock valued at $98,599,000 after purchasing an additional 119,694 shares during the period. JPMorgan Chase & Co. lifted its position in shares of LeMaitre Vascular by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,376 shares of the medical instruments supplier’s stock valued at $595,000 after acquiring an additional 4,020 shares during the period. MetLife Investment Advisors LLC lifted its position in shares of LeMaitre Vascular by 58.0% during the 3rd quarter. MetLife Investment Advisors LLC now owns 12,092 shares of the medical instruments supplier’s stock valued at $468,000 after acquiring an additional 4,441 shares during the period. Wells Fargo & Company MN lifted its position in shares of LeMaitre Vascular by 51.8% during the 3rd quarter. Wells Fargo & Company MN now owns 220,289 shares of the medical instruments supplier’s stock valued at $8,533,000 after acquiring an additional 75,165 shares during the period. Finally, Cadence Capital Management LLC lifted its position in shares of LeMaitre Vascular by 20.1% during the 3rd quarter. Cadence Capital Management LLC now owns 83,497 shares of the medical instruments supplier’s stock valued at $3,235,000 after acquiring an additional 13,984 shares during the period. 81.78% of the stock is currently owned by hedge funds and other institutional investors.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Featured Story: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.